J Biomed 2016; 1:32-35. doi:10.7150/jbm.16927 This volume
Neoadjuvant Chemotherapy Followed by Radiotherapy for Laryngeal Cancer
1. Ear, Nose and Throat Department, “Saint Luke” Private Hospital, Panorama, Thessaloniki, Greece;
2. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
3. General Surgery Department, “Genisis” Private Clinic, Thessaloniki, Greece;
4. Department of Maxillofacial Surgery, University General Hospital of Alexandroupolis, Alexandroupolis, Greece;
5. Department of Anatomy, Democritus University of Thrace, Alexandroupolis, Greece.
Karapantzos I, Karapantzou C, Zarogoulidis P, Karanikas M, Thomaidis V, Charalampidis C. Neoadjuvant Chemotherapy Followed by Radiotherapy for Laryngeal Cancer. J Biomed 2016; 1:32-35. doi:10.7150/jbm.16927. Available from /v01p0032.htm
Early stage of diagnosis is crucial for laryngeal cancer since the organ and function preservation is wanted from the treating physicians. Currently the optimal care of patients with laryngeal cancer is truly multidisciplinary, with progressive advances in surgical, radiation, and medical oncology. Moreover; molecular targeted therapies are on their way.
Take home message: The treatment of patients with laryngeal cancer with systemic therapy represents an opportunity to positively impact functional outcomes with an anatomically and functionally preserved larynx. Future challenges include identification of novel molecular pathways that upregulate tumorigenesis and suppression of these.
Keywords: laryngeal cancer, chemotherapy, radiotherapy, molecular therapy.